Interested in Connecting? Please contact: Tassos Nicolaou CEO firstname.lastname@example.org
Message the company or request a 1:1 meeting here.
Delpor is a clinical stage biopharmaceuticals company that develops once-yearly therapies for chronic conditions. The technology makes it possible for patients to achieve complete medication adherence for one full year without having to worry about taking their meds. Patients may go through a year without any symptoms, relapses, the stigma of taking medication, or the daily reminder that they are sick, almost like having a one-year cure in a disease area where there is no cure. The company is focusing on CNS indications pursuing 6-12 month formulations of drugs targeting Mental Disorders, Addiction, Neuromuscular Diseases, Neurodegenerative Diseases, and other conditions. Delpor’s lead product is a 1-Year Risperidone for schizophrenia maintenance which is currently in clinical development.